Zobrazeno 1 - 10
of 18
pro vyhledávání: ''
Autor:
Yoshihiko Hirohashi, Emi Mizushima, Munehide Nakatsugawa, Noriyuki Sato, Makoto Emori, Toshihiko Torigoe, Takayuki Kanaseki, Tomohide Tsukahara, Yuji Shibayama, Toshihiko Yamashita, Kenji Murata, Terufumi Kubo
Publikováno v:
Cancer Science
Chemotherapy has improved the prognosis of patients with sarcomas. However, it may suppress anti-tumor immunity. Recently, we reported a novel CD8+ memory T cell population with a chemo-resistance property, “young memory” T (TYM) cells. In this s
Autor:
Hiromitsu Mimata, Wataru Obara, Fuminori Sato, Tamotsu Sugai, Yusuke Nakamura, Ryo Takata, Tomoaki Fujioka, Renpei Kato, Yoichiro Kato, Mitsugu Kanehira, Kazuyoshi Takeda
Publikováno v:
Cancer Science
We screened cell division associated 1 (CDCA1) as an oncogene that is overexpressed on several cancers, including prostate cancer. We also identified a highly immunogenic HLA-A*2402-restricted epitope peptide corresponding to part of the CDCA1 protei
Autor:
Hiroaki Tanaka, Hiroto Hayashi, Haruo Iguchi, Nobuaki Suzuki, Yasunobu Koki, Tomio Ueno, Yusuke Nakamura, Tetsuya Ikemoto, Hideki Arima, Hiroyuki Furukawa, Kosei Hirakawa, Hiroaki Nagano, Masaaki Oka, Yoshitaro Shindo, Hiroto Matsui, Hiroko Takenouchi, Ryoichi Shimizu, Kazuhiro Uesugi, Kazuhiko Yoshimatsu, Toshiyoshi Fujiwara, Hidenobu Ishizaki, Michihisa Iida, Shoichi Hazama, Koichiro Sakata, Yuzo Umeda, Shigefumi Yoshino, Takashi Hatori, Mitsuo Shimada, Atsushi Aruga
Publikováno v:
Cancer Science
We previously conducted a phase I clinical trial combining the HLA-A*2402-restricted KIF20A-derived peptide vaccine with gemcitabine for advanced pancreatic cancer (PC) and confirmed its safety and immunogenicity in cancer patients. In this study, we
Autor:
Shigeki Shichijo, Kyogo Itoh, Rin Yamaguchi, Akira Yamada, Akihiko Kawahara, Nobukazu Komatsu, Masayoshi Kage, Hirokazu Shoji, Yoshitaka Honma, Yuji Heike, Satoru Iwasa, Yasuhide Yamada, Satoko Matsueda, Michi Morita, Tetsuro Sasada, Natsuki Tanaka
Publikováno v:
Cancer Science
A phase I study of a new cancer vaccine (KRM-10), consisting of a mixture of 10 different short peptides, was conducted for patients with advanced gastrointestinal cancers. Primary or secondary endpoints included the dose-limiting toxicity (DLT), or
Autor:
Shigeki Shichijo, Teppei Yamada, Tetsuro Sasada, Masanori Noguchi, Uhi Toh, Shinzo Takamori, Akira Yamada, Shinjiro Sakamoto, Noboru Hattori, Shigetaka Suekane, Kouichiro Kawano, Kyogo Itoh, Shigeru Yutani, Nobuoki Kohno, Satoko Matsueda
Publikováno v:
Cancer Science
To develop a peptide vaccine for cancer patients with the HLA-A26 allele, which is a minor population worldwide, we investigated the immunological responses of HLA-A26+ ⁄ A26+ cancer patients to four different CTL epitope peptides under personalize
Autor:
Shinzo Takamori, Satoko Matsueda, Akira Yamada, Shinjiro Sakamoto, Kyogo Itoh, Yasuhiro Terazaki, Kayoko Waki, Teppei Yamada, Nobukazu Komatsu, Koichi Yoshiyama, Shunichi Sugawara
Publikováno v:
Cancer Science
PD-1 expression in peripheral blood T-cells has been reported in several kinds of cancers, including lung cancer. However, the relationship between PD-1 expression in peripheral blood T-cells and prognosis after treatment with a cancer vaccine has no
Autor:
Koichi Ohshima, Yukinao Ishibashi, Ryuya Yamanaka, Satoko Matsueda, Kouichirou Kawano, Masayoshi Kage, Shigeki Shichijo, Koji Hiraoka, Kyogo Itoh, Akihiko Kawahara, Kazuo Shirouzu, Ryuji Takahashi, Tetsuro Sasada
Publikováno v:
Cancer Science
Refractory bone and soft tissue sarcomas are challenging diseases to treat because of their robustness to chemotherapy. Although cancer vaccines have the potential to become an attractive treatment modality, their progress has been hampered by the pr
Autor:
Koichi Hirata, Goro Kutomi, Akari Takahashi, Yoshihiko Hirohashi, Hidekazu Kameshima, Hiroaki Shima, Yuji Iwayama, Yasuaki Tamura, Takayuki Kanaseki, Toshihiko Torigoe, Tetsuhiro Tsuruma, Yasutoshi Kimura, Noriyuki Sato, Tomohide Tsukahara, Masahumi Imamura
Publikováno v:
Cancer Sci
Survivin, a member of the inhibitor of apoptosis protein (IAP) family containing a single baculovirus IAP repeat domain, is highly expressed in cancerous tissues but not in normal counterparts. Our group identified an HLA‐A24‐restricted antigenic
Autor:
Mayumi Kurimura, Masakatsu Hishizawa, Jun Okamura, Yukiko Shimizu, Atsuhiko Hasegawa, Kiyoshi Kurihara, Nanae Harashima, Ayako Takamori, Takao Masuda, Toshiki Watanabe, Yoshihisa Yamano, Fumiaki Kondo, Atae Utsunomiya, Mari Kannagi
Publikováno v:
Cancer Science. 100:481-489
Human T-cell leukemia virus type-1 (HTLV-1)-specific T-cell immunity, a potential antitumor surveillance system in vivo, is impaired in adult T-cell leukemia (ATL). In this study, we aimed to clarify whether the T-cell insufficiency in ATL is present
Autor:
Kyogo Itoh, Soichiro Takai, Shigenori Honma, Akira Yamada, Masahiro Tanaka, Masaaki Oka, Sohei Satoi, Kanji Takahashi, Koutaro Yamamoto, Kimika Nakahara, Naoyoshi Terakawa, Yasuo Kamiyama, Takashi Mine, Hiroaki Yanagimoto, Junko Mizoguchi
Publikováno v:
Cancer Science. 98:605-611
The aim of the present study was to investigate the safety and immune responses of personalized peptide vaccination when administered with gemcitabine (GEM) in advanced pancreatic cancer (APC) patients. Thirteen patients with APC were enrolled. Pre-v